BioCentury | Jan 11, 2016
Company News

Cosmo, Ferring deal

...Cosmo granted Ferring exclusive rights to develop and commercialize Cortiment MMX in Japan. Ferring already has ex-U.S...
...Cosmo and will be responsible for conducting clinical trials required for a Japanese regulatory submission. Cortiment MMX...
BioCentury | Jul 13, 2015
Company News

Ferring, NovaMedica deal

...Prepopik sodium picosulfate/magnesium oxide/citric acid, a laxative for cleansing the colon as preparation for colonoscopy; Cortiment MMX...
BioCentury | Mar 9, 2015
Company News

Ferring sales and marketing update

...Ferring launched Cortiment MMX budesonide in Europe to treat adults with active mild to moderate ulcerative colitis...
BioCentury | Nov 7, 2014
Top Story

Salix hit on accounting turmoil

...2016. It singled out broad-spectrum antibiotic Xifaxan and ulcerative colitis treatments Apriso granulated mesalamine and Uceris...
BioCentury | Nov 3, 2014
Clinical News

Cortiment MMX budesonide regulatory update

...Cosmo and Ferring said Cortiment MMX budesonide received approval in 27 EU countries under the Mutual Recognition...
...2013 and plans to launch it in the additional 27 countries in the "coming months." Cortiment MMX...
...Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy Ferring Pharmaceuticals A/S , Saint-Prex, Switzerland Product: Cortiment MMX budesonide ( Uceris...
BioCentury | Oct 13, 2014
Clinical News

Uceris budesonide rectal foam regulatory update

...FDA granted final approval to Uceris budesonide rectal foam from Salix for the induction of remission...
...Salix plans to launch the product next quarter. Salix markets a once-daily tablet formulation of Uceris...
...2008). Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Dr. Falk Pharma GmbH , Freiburg, Germany Product: Uceris...
BioCentury | Oct 9, 2014
Company News

FDA approves Uceris rectal foam

...FDA approved an NDA for Uceris budesonide rectal foam from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to induce...
...formulation of the glucocorticosteroid in 1Q15. The company currently markets a once-daily tablet formulation of Uceris...
...Santarus licensed Uceris from Cosmo Pharmaceuticals S.p.A. (SIX:COPN) in 2008. Also on Wednesday, Cosmo said Uceris...
BioCentury | Oct 6, 2014
Clinical News

Uceris budesonide rectal foam regulatory update

...FDA granted tentative approval to an NDA for Uceris budesonide rectal foam from Salix for the...
...quarter and launch Uceris rectal foam in 1Q15. Salix markets a once-daily tablet formulation of Uceris...
...2008). Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Dr. Falk Pharma GmbH , Freiburg, Germany Product: Uceris...
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...CB-01-11 ), methylene blue MMX and Uceris budesonide MMX - as well as Japanese patents for Uceris...
BioCentury | Jul 14, 2014
Company News

Salix Pharmaceuticals Ltd, Cosmo deal

...MMX , methylene blue MMX and Uceris budesonide MMX - as well as Japanese patents for Uceris...
...East, excluding Australia and New Zealand. Salix already has U.S. rights to ulcerative colitis drug Uceris...
...blue delivered using MMX technology - is in Phase III testing to detect colorectal cancer. Uceris...
Items per page:
1 - 10 of 64